Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)

  title={Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)},
  author={Peter G. E. Kennedy},
  journal={The Lancet Neurology},
  • P. Kennedy
  • Published 1 February 2013
  • Medicine
  • The Lancet Neurology

Figures from this paper

Human African Trypanosomiasis: A Highly Neglected Neurological Disease
The recent decline in the number of reported new HAT cases should not foster further neglect of this highly neglected nervous system infection, and stage biomarkers and safer therapy are urgently needed.
Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis
Clinical features of HAT are diverse and non-specific with early-stage symptoms common to several infections endemic within sub-Saharan Africa which may result in a delayed or mistaken diagnosis and further research is required to develop better diagnostic and staging techniques and safer more efficacious drug regimens.
Human african trypanosomiasis: current standing and challenges
Information is compiled on the history of the clinical aspects of HAT, its epidemiology, diagnosis, therapy, and prophylaxis, as well as updating information on the current panorama and perspectives regarding the disease.
Congenital Trypanosomiasis in Child Born in France to African Mother
To the Editor: Sleeping sickness, or human African trypanosomiasis, is a neglected tropical parasitic infection transmitted by the tsetse fly bite. In central and western Africa, trypanosomiasis is
Role of Serodiagnosis of Human African Trypanosomiasis (Sleeping Sickness)
Human  African  trypanosomiasis  (HAT) or  sleeping  sickness,  is  caused  by  Trypanosoma  brucei  gambiense,  which  is  a  chronic form of the disease present in western and central Africa and
Update on human African trypanosomiasis (sleeping sickness)
  • P. Kennedy
  • Medicine, Biology
    Journal of Neurology
  • 2019
An overview of some important recent developments in human African trypanosomiasis covers various aspects including a reduction in disease incidence, newly recognised parasite reservoir sites in humans, disease outcome, novel diagnostic methods, new and improved treatment, and disease neuropathogenesis.
The challenging problem of disease staging in human African trypanosomiasis (sleeping sickness): a new approach to a circular question.
This work proposes an alternative 'reverse' approach to address the problem of staging in HAT, conceptualised as using appropriate statistical methods to test the performance of combinations of established laboratory variables as staging biomarkers to correlate with the CSF WBC/trypanosomes and clinical features of HAT.
African Trypanosomiasis as Paradigm for Involvement of the Mononuclear Phagocyte System in Pathogenicity During Parasite Infection
The parasite–host interactions with a focus on the role played by cells of the MPS and parasite-derived components triggering immune responses during the different stages/phases of experimental trypanosome infections and the contribution of cells ofThe MPS to immunopathogenicity development with focus on liver injury and anemia are discussed.


Diagnostic and neuropathogenesis issues in human African trypanosomiasis.
  • P. Kennedy
  • Biology, Medicine
    International journal for parasitology
  • 2006
Human African trypanosomiasis in endemic populations and travellers
The symptomatology of travellers is markedly different from the usual textbook descriptions of African HAT patients and a promising new drug combination is currently evaluated in a phase 3 b study and further new drugs are under evaluation.
The continuing problem of human African trypanosomiasis (sleeping sickness)
  • P. Kennedy
  • Medicine, Biology
    Annals of neurology
  • 2008
There is a pressing need for an effective, safe oral drug for both stages of the disease, but this will require a significant increase in investment for new drug discovery from Western governments and the pharmaceutical industry.
Options for Field Diagnosis of Human African Trypanosomiasis
There is an urgent need for better tools for the field diagnosis of this neglected disease, and improved access to diagnosis and treatment for the population at risk remains the greatest challenge for the coming years.
Untreated Human Infections by Trypanosoma brucei gambiense Are Not 100% Fatal
It is demonstrated that a number of human African trypanosomiasis patients from the Ivory Coast display such infection courses, recognising that trypanotolerance exists in humans, as is now widely accepted for animals, is a major step forward for future research in the field of HAT.
Human African trypanosomiasis
There have been resurgences of the disease in recent years, often due to breakdown in public health systems for various reasons, and two articles in this issue of Neurology serve as a reminder that this disease can be imported to other countries.
Melarsoprol Cyclodextrin Inclusion Complexes as Promising Oral Candidates for the Treatment of Human African Trypanosomiasis
Two melarsoprol cyclodextrin inclusion complexes are investigated and found that these compounds retain trypanocidal properties in vitro and cure CNS-stage murine infections when delivered orally, once per day for 7-days, at a dosage of 0.05 mmol/kg.
Clinical Presentation of T.b. rhodesiense Sleeping Sickness in Second Stage Patients from Tanzania and Uganda
Background A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease
Focus–Specific Clinical Profiles in Human African Trypanosomiasis Caused by Trypanosoma brucei rhodesiense
A retrospective cohort study providing detailed clinical profiles of 275 HAT patients recruited in two northern foci (Uganda) and one southern focus (Malawi) in East Africa establishes focus-specific HAT clinical phenotypes showing dramatic variations in disease severity and rate of stage progression both between northern and southern East African foci and between Ugandan foci.
Identification of stage biomarkers for human African trypanosomiasis.
Human African trypanosomiasis (HAT), caused by infection with sub-species of Trypanosoma brucei (T. b.), manifests as a hemolymphatic stage followed by an encephalitic stage. The distinction of the